| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 江苏联环药业股份有限公司诞生于1999年12月，由成立于1958年的扬州制药厂发起创建。2003年3月，公司实现A股上市。经过多年的改革创新发展，江苏联环药业股份有限公司已成长为集研发、生产、销售为一体的国家高新技术企业，位列中国制药工业百强企业，并取得了一系列的发展成果。拥有扬州联环医药营销、联环（南京）医疗科技、南京联智医药科技、成都亚中生物制药等多家子企业。 公司目前已形成以院士工作站、博士工作站为依托的南京、扬州两个研发平台，与中科院上海药研所、中国药科大学等大院大所建立了良好的技术合作关系，迄今为止，已研发出包括国家一类新药在内的10多个国家级新药和若干个仿制药，并获得多项发明专利。公司产品涵盖泌尿系统类（主要有爱普列特、特拉唑嗪等品种）、抗组胺类（主要有依巴斯汀片、特非那定片等品种）、心血管类（主要有非洛地平片、辛伐他汀片等品种）、甾体激素类（主要有注射用硫酸普拉睾酮钠、达那唑胶囊等品种）和抗生素类（主要有阿奇霉素片、盐酸多西环素片等品种）五大系列。 近年来，联环药业坚持科技创新，追求绿色发展，着力打造现代化制药企业，公司在“二次创业”新征程上正奋楫扬帆、加速前行。 | ||||||||||||||||||||||||
| Main Business | 研制、开发、生产和销售原料药和药物制剂。 | ||||||||||||||||||||||||
| Legal Representative | 钱振华 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 钱振华 | ||||||||||||||||||||||||
| Solicitors | 北京市竞天公诚律师事务所 | ||||||||||||||||||||||||
| Auditors | 天衡会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0514-87813082 | ||||||||||||||||||||||||
| Fax No | 0514-87815079 | ||||||||||||||||||||||||
| Website | www.lhpharma.com | ||||||||||||||||||||||||
| lhgf@lhpharma.com；yujuan_1@126.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 19/03/2003 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.470 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.150 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 4.744 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 2.883B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |